Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GRFS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| von Willebrand Factor | Hemophilia A, Congenital | Phase 2 · NCT03095287 | Terminated |
| plasma-derived FVIII/VWF concentrate | Von Willebrand Disease | Phase 4 · NCT02472665 | Withdrawn |
| Therapeutic Immune Globulin | Primary Immunodeficiency | Phase 4 · NCT04566692 | Completed |
| Alphanate SD/HT | Von Willebrand Disease | Phase 4 · NCT00555555 | Terminated |
| Coagulation Factor VIII | Hemophilia A | Phase 4 · NCT04621916 | Unknown |
| Human Immunoglobulin G | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 3 · NCT07540221 | Recruiting |
| Immune Globulin Subcutaneous Human | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 3 · NCT07540221 | Recruiting |
| SMT + PE-A 5% | Acute-On-Chronic Liver Failure | Phase 3 · NCT03702920 | Terminated |
| Plasma-derived AT-III concentrate | Antithrombin III Deficiency | Phase 2/3 · NCT00319228 | Terminated |
| IVIG-PEG | Primary Immunodeficiency | Phase 3 · NCT04561115 | Completed |
| 0.9% sodium chloride | COVID-19 | Phase 3 · NCT04847141 | Terminated |
| Fibrin Sealant Grifols | Excessive Bleeding During Surgery | Phase 3 · NCT03461406 | Completed |
| EVICEL | Excessive Bleeding During Surgery | Phase 3 · NCT03461406 | Completed |
| Fibrinogen | Congenital Afibrinogenemia | Phase 3 · NCT04636268 | Withdrawn |
| C19-IG 20% | COVID-19 | Phase 3 · NCT04847141 | Terminated |
| Albutein 20% | Decompensated Cirrhosis and Ascites | Phase 3 · NCT03451292 | Completed |
Also used in these trials (approved or third-party drugs, not GRFS's own candidates): Emicizumab, Methotrexate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GRFS holds $486M in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GRFS files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRFS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →